Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a clinical stage genetic medicines company whose news flow centers on the development of its lead gene therapy candidate, PBFT02, for neurodegenerative diseases. Company updates frequently highlight progress in the Phase 1/2 upliFT-D trial in frontotemporal dementia with GRN or C9orf72 mutations, including cohort enrollment, dosing milestones, and interim biomarker and safety data.
Investors following PASG news can expect regular announcements of quarterly and annual financial results, where Passage Bio reports research and development spending, general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities, along with commentary on expected cash runway. These releases often include recent business highlights related to PBFT02, such as data readouts on cerebrospinal fluid progranulin levels, plasma neurofilament light chain trends, and protocol amendments intended to refine the benefit–risk profile of the program.
News items also cover regulatory and manufacturing developments, including interactions with the U.S. Food and Drug Administration on analytical comparability for a high-productivity, suspension-based PBFT02 manufacturing process, and plans to seek feedback on potential registrational trial designs. In addition, Passage Bio regularly announces participation in healthcare, genetic medicines, and biopharma investor conferences, where management presents corporate overviews and program updates.
This page aggregates these disclosures, offering a centralized view of Passage Bio’s clinical, regulatory, financial, and corporate communications. Readers interested in PASG can use this news feed to track the evolution of the PBFT02 program, changes in trial design, manufacturing strategy, and key financial and listing-related events such as the company’s reverse stock split and subsequent confirmation of compliance with Nasdaq listing requirements.
Passage Bio (NASDAQ: PASG) announced participation in two virtual investor conferences in March 2021. The first is the Barclay’s Global Healthcare Conference on March 10, at 4:10 p.m. ET, featuring a presentation format. The second event is the Stifel 3rd Annual CNS Day on March 31, at 10:00 a.m. ET, in a fireside chat format. Both events will be webcast live, with replays available for 30 days. Passage Bio focuses on gene therapies for rare central nervous system disorders, collaborating with the University of Pennsylvania's Gene Therapy Program.
Passage Bio (NASDAQ: PASG) announced a conference call on March 3, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2020 financial results. This call will provide key insights into the company's recent business highlights. Investors can join via phone or through a live audio webcast. The call will be archived for 30 days. Based in Philadelphia, Passage Bio is focused on developing gene therapies for rare central nervous system disorders, collaborating with the University of Pennsylvania to further its preclinical work and enhance its pipeline.
Passage Bio (Nasdaq: PASG) has appointed Dr. Maxine Gowen to its board of directors, effective February 18, 2021. Dr. Gowen, CEO of Tamuro Bio, brings extensive leadership experience from her tenure at Trevena and GSK. Her expertise is expected to support Passage Bio's transition into a clinical development organization. Simultaneously, Dr. Stephen Squinto has resigned from his board position after significant contributions, including advancing the company’s pipeline and supporting its IPO. Passage Bio aims to develop transformative gene therapies for rare CNS disorders.
Passage Bio (Nasdaq: PASG) announced FDA clearance for its IND application for PBKR03, a gene therapy targeting early infantile Krabbe disease, with clinical trials expected to start in 1H21. Krabbe disease, a rare CNS disorder, lacks approved therapies, highlighting the urgency of this development. PBKR03 utilizes a proprietary AAV capsid for gene delivery, aiming to restore GALC activity in affected patients. Preclinical studies show promising results, indicating potential for improved myelination and survival rates.
Passage Bio, Inc. (Nasdaq: PASG) announced FDA clearance for the IND application of PBFT02, a gene therapy for Frontotemporal Dementia (FTD) with GRN mutations, a condition with no approved disease-modifying treatments. Preclinical data from the University of Pennsylvania demonstrated PBFT02’s potential to elevate PGRN levels in the brain and cerebrospinal fluid while reducing lysosomal storage lesions. A Phase 1/2 clinical trial is expected to commence in H1 2021, focusing on safety, tolerability, and biomarker assessment, with initial data anticipated by late 2021 or early 2022.
Passage Bio, Inc. (Nasdaq: PASG) has priced its public offering of 7 million shares of common stock at $22.00 per share, aiming to raise $154 million in gross proceeds. The offering, which includes a 30-day option for underwriters to purchase an additional 1.05 million shares, is expected to close around January 26, 2021. The proceeds will support the company's efforts in gene therapies for rare central nervous system disorders. J.P. Morgan, Goldman Sachs, and Cowen are the joint bookrunning managers for the offering.
Passage Bio (Nasdaq: PASG) has announced a public offering of 7,000,000 shares of its common stock, with an additional 1,050,000 shares available through underwriters' options. This offering is intended to raise capital for the company's operations focusing on gene therapies for rare neurological disorders. J.P. Morgan, Goldman Sachs, and Cowen are managing the offering. The registration is pending approval from the SEC, and the offering's completion is uncertain.
Passage Bio (Nasdaq: PASG) announced a series of virtual Research & Development events for 2021, starting on January 25. The first event will focus on the investigational therapy PBGM01 targeting infantile GM1 gangliosidosis. Presenters include CEO Bruce Goldsmith, Chief Scientific Advisor James M. Wilson, and Chief Medical Officer Gary Romano, who will discuss the therapy's development and trial design. GM1 is a rare genetic disorder with a life expectancy of 2-4 years for infants. PBGM01 aims to deliver a functional GLB1 gene to mitigate neurodegeneration.
Passage Bio (Nasdaq: PASG) has submitted IND applications for PBFT02 aimed at treating Frontotemporal Dementia with Granulin Mutation and PBKR03 for Krabbe Disease. The company plans to initiate three clinical studies in the first half of 2021. It is also advancing PBML04 for Metachromatic Leukodystrophy into IND-enabling studies. Passage Bio continues to collaborate with the University of Pennsylvania’s Gene Therapy Program, having licensed a total of 17 programs. A new manufacturing lab will open in Q2 2021 to enhance testing capabilities.
On January 4, 2021, Passage Bio (Nasdaq: PASG) announced that its CEO, Bruce Goldsmith, will present a company overview at the J.P. Morgan 39th Annual Healthcare Conference on January 11, 2021, at 7:30 AM ET. A live webcast of the presentation will be available on the company's website for 30 days. Passage Bio focuses on developing gene therapies for rare central nervous system disorders, leveraging collaboration with the University of Pennsylvania’s Gene Therapy Program to advance its pipeline.